glp 1 drugs for rheumatoid arthritis GLP-1 Medications and Arthritis: What a New Study Shows Glucagon-like peptide and its receptor

Review findings The review confirms that incretin-based therapies have not only achieved their intended goal of T2D and obesity management but have also demonstrated clinically meaningful benefits across multiple organ systems

In contrast to PIO, rosiglitazone was not shown to promote histologic improvements of NASH during a 12-month well-organized study [65]

The superior FPG lowering with combination therapy versus GLP-1RA is also clinically relevant

Still, genetics explains only a portion of treatment heterogeneity, and routine pharmacogenomic screening is not yet ready for widespread clinical use, he added

[DOI] [PubMed] [Google Scholar] 58

So we think of it really as a disease in which we have a treatment for it that we can hopefully put the individual control it and hopefully put them in remission but currently it only works if you take the medication